U.S. Hormone Replacement Therapy Market - By Product (Estrogen, Progesterone, Thyroid, Growth Hormone, Testosterone), Route of Administration (Oral, Parenteral), Disease (Menopause, Growth Hormone Deficiency), Distribution Channel, Forecast 2023-2032

U.S. Hormone Replacement Therapy Market - By Product (Estrogen, Progesterone, Thyroid, Growth Hormone, Testosterone), Route of Administration (Oral, Parenteral), Disease (Menopause, Growth Hormone Deficiency), Distribution Channel, Forecast 2023-2032

U.S. hormone replacement therapy market size is projected to expand at 6.5% CAGR from 2023 to 2032. The aging population, particularly among baby boomers, is increasing the prevalence of hormonal imbalances and age-related conditions, fueling the demand for hormone replacement therapies (HRTs) in the country.

The rising advancements in hormone therapies is leading to the growing awareness of the benefits of HRT in managing menopausal symptoms and age-related disorders. For instance, in June 2023, Pfizer Inc. and OPKO Health Inc. announced FDA approval for NGENLA (somatrogon-ghla), a weekly human growth hormone analog, indicated for treating growth failure in pediatric patients aged 3 years and older due to insufficient secretion of endogenous growth hormone. Furthermore, the ongoing R&D activities for innovative hormone replacement formulations and delivery methods is making way for enhanced treatment options. Additionally, the changing lifestyles, rising healthcare expenditure, and the proactive approach to women health in the U.S. will drive the market growth.

The U.S. hormone replacement therapy industry is segregated into product, route of administration, disease type, and distribution channel.

Based on product, the industry value from the growth hormone replacement therapy segment is projected to rise at 6.9% CAGR through 2032. This is owing to the increasing awareness and diagnosis of growth hormone deficiencies in the region. The higher advancements in therapeutic formulations, and the rising demand for effective treatments among pediatric patients with growth disorders will also drive the segment growth ahead.

U.S. hormone replacement therapy market share from the hypothyroidism disease type segment is estimated to witness 5.6% CAGR from 2023 to 2032, due to the rising incidence of thyroid disorders and the growing awareness for early diagnosis. The increasing advancements in hormone replacement formulations and the surging patient preference for effective hypothyroidism management will also boost the segment growth.

The market value from the parenteral route of administration segment is anticipated to register 7% CAGR through 2032. The growth can be attributed to the increasing preference for direct and controlled delivery of hormones, rapid onset of action, and improved treatment compliance. Patient convenience coupled with higher advancements in parenteral administration technologies will also fuel the adoption of parenteral administration for HRTs in the country.